This phase I trial is evaluating the safety and recommended dose of an immunotherapy drug alone and in combination for the treatment of patients with advanced solid cancers.
This trial is treating patients with advanced solid cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
This is a non-randomised trial, in which patients will be sequentially assigned to receive Varying Doses of AB154 Monotherapy, and varying doses of AB154 in combination with the selected dose of AB122.
Recruiting Hospitals Read More